---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-21-000075"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2021-11-29T23:59:59+00:00"
generated_at: "2026-06-28T05:05:02.806372+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Appoints Daniel Faga as Class I director effective Nov 26, 2021

## Summary
- Daniel Faga appointed to board as Class I director, effective immediately on Nov 26, 2021.
- Received option for 2,321 shares at closing price on appointment date, vesting fully on Feb 10, 2022.
- Also granted option for 11,000 shares at same exercise price, vesting monthly over three years.
- Company entered into standard indemnification agreement with Faga.

## SEC filing metadata
- accession: 0001370053-21-000075
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2021-11-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005321000075/0001370053-21-000075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005321000075/anab-20211126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-21-000075
- JSON: https://secwatch.observer/filing/0001370053-21-000075.json
- Plain text: https://secwatch.observer/filing/0001370053-21-000075.txt

## Key facts
- Executive change
  Daniel Faga was appointed as Class I Director at ANAPTYSBIO, INC.
  - Action: appointed
  - Role: Class I Director
  source text: On November 26, 2021, AnaptysBio, Inc. (the “Company”) appointed Mr. Daniel Faga, as a Class I director on its board of directors (the “Board”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1370053/000137005321000075/0001370053-21-000075-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.